Patients on Soliris® Needed Fewer Transfusions
73% Reduction in Mean Number of Units Transfused Across All Patient Subgroups 1
- 51% of Soliris patients achieved transfusion independence vs. 0% of patients not on Soliris1
- 44% reduction in transfusion requirements for Soliris patients who still required some transfusions1
- Soliris helps stabilize hemoglobin levels by protecting against PNH red blood cell lysis1
- 49% maintained hemoglobin levels without transfusions over 26 weeks1
IMPORTANT SAFETY INFORMATION
WARNING: SERIOUS MENINGOCOCCAL INFECTIONS
Soliris increases the risk of meningococcal infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early
- Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of Soliris; revaccinate according to current medical guidelines for vaccine use
- Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary
The effect of withdrawal of anticoagulant therapy during Soliris treatment has not been established. Therefore, treatment with Soliris should not alter anticoagulant management.
The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, and fatigue.
SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.
References: 1. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243. 2. Schubert J, Hillmen P, Röth A, et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2008;142: 263-272. 3. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840-1847. 4. Socié G, Hillmen P, Muus P, et al. Sustained improvements in transfusion requirements, fatigue and thrombosis with eculizumab treatment in paroxysmal nocturnal hemoglobinuria [ASH abstract]. Blood. 2007;110: Abstract 3672.